Gilead’s CAR-T therapy Yescarta now available via NHS Scotland for two forms of B-cell lymphoma

pharmafile | October 8, 2019 | News story | Manufacturing and Production, Sales and Marketing CAR T, CAR-T, NHS, Scotland, Scottish Medicines Consortium, pharma 

News has broken that the Scottish Medicines Consortium (SMC) has chosen to approve the use of Gilead’s chimeric antigen receptor T cell (CAR-T) therapy Yescarta (axicabtagene ciloleucel) on the NHS in Scotland.

Following the decision, patients will be able to receive the therapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), in adult patients who have tried two or more lines of systemic therapy.

The ruling marks the second NHS approval of a CAR-T therapy in Scotland, following Novartis’ Kymriah (tisagenlecleucel) earlier this year for the treatment of relapsed/refractory DLBCL in adults and acute lymphoblastic leukaemia.

“This is further good news for people affected by lymphoma as it means there is wider access to CAR T cell therapy in Scotland. It is important for people affected by DLBCL and particularly significant for people affected by primary mediastinal B-cell lymphoma, for whom CAR T cell therapy would not otherwise be available in Scotland,” remarked Stephen Scowcroft, Director of Operations and External Affairs at Lymphoma Action.

General Manager, Gilead UK & Ireland’s General Manager Hilary Hutton-Squire also remarked: “This is an important day for patients in Scotland with certain aggressive forms of blood cancer. Yescarta is an individualised cell therapy that provides a valuable treatment option for patients who have exhausted other therapies, meaning they may have just months left to live, potentially changing their outcomes.” 

Matt Fellows

Related Content

Novo Nordisk launches Wegovy in the UK

Novo Nordisk has today announced that Wegovy (semaglutide injection) is now available in the UK …

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo

On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …

Latest content